Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
The method involves in-depth molecular simulations of the ion channel in its native membrane environment, including its open, closed, and inactivated states, along with ensemble virtual screening that focuses on conformational mobility for each state. Tentative binding pockets are identified inside the pore, in the gating area, and at allosteric sites to address every conceivable mechanism of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O60840
UPID:
CAC1F_HUMAN
Alternative names:
Voltage-gated calcium channel subunit alpha Cav1.4
Alternative UPACC:
O60840; A6NI29; F5CIQ9; O43901; O95226; Q9UHB1
Background:
The Voltage-dependent L-type calcium channel subunit alpha-1F, also known as Cav1.4, plays a crucial role in the entry of calcium ions into excitable cells. It is pivotal in various calcium-dependent processes such as muscle contraction, hormone release, and cell death. This protein generates L-type calcium currents, activating at more negative voltages without undergoing calcium-dependent inactivation.
Therapeutic significance:
Cav1.4 is implicated in several retinal disorders, including congenital stationary night blindness, cone-rod dystrophy, and Aaland island eye disease. These conditions highlight the protein's significance in visual function and underscore the potential of targeting Cav1.4 in therapeutic strategies aimed at mitigating visual impairment.